PEPG Strangle Strategy
PEPG (PepGen Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
PEPG (PepGen Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $117.6M, a beta of 1.93 versus the broader market, a 52-week range of 1.01-7.8, average daily share volume of 1.4M, a public-listing history dating back to 2022, approximately 56 full-time employees. These structural characteristics shape how PEPG stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.93 indicates PEPG has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on PEPG?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current PEPG snapshot
As of June 26, 2026, spot at $1.67, ATM IV 256.20%, IV rank 44.13%, expected move 73.45%. The strangle on PEPG below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 21-day expiry.
Why this strangle structure on PEPG specifically: PEPG IV at 256.20% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 73.45% (roughly $1.23 on the underlying). The 21-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PEPG expiries trade a higher absolute premium for lower per-day decay. Position sizing on PEPG should anchor to the underlying notional of $1.67 per share and to the trader's directional view on PEPG stock.
PEPG strangle setup
The PEPG strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PEPG near $1.67, the first option leg uses a $1.75 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PEPG chain at a 21-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PEPG shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.75 | N/A |
| Buy 1 | Put | $1.59 | N/A |
PEPG strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
PEPG strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on PEPG. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on PEPG
Strangles on PEPG are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PEPG chain.
PEPG thesis for this strangle
The market-implied 1-standard-deviation range for PEPG extends from approximately $0.44 on the downside to $2.90 on the upside. A PEPG long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current PEPG IV rank near 44.13% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on PEPG should anchor more to the directional view and the expected-move geometry. As a Healthcare name, PEPG options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PEPG-specific events.
PEPG strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PEPG positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PEPG alongside the broader basket even when PEPG-specific fundamentals are unchanged. Always rebuild the position from current PEPG chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on PEPG?
- A strangle on PEPG is the strangle strategy applied to PEPG (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With PEPG stock trading near $1.67, the strikes shown on this page are snapped to the nearest listed PEPG chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are PEPG strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the PEPG strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 256.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a PEPG strangle?
- The breakeven for the PEPG strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PEPG market-implied 1-standard-deviation expected move is approximately 73.45%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on PEPG?
- Strangles on PEPG are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PEPG chain.
- How does current PEPG implied volatility affect this strangle?
- PEPG ATM IV is at 256.20% with IV rank near 44.13%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.